94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Qinyuan Gong1,2
Rongzhen Xu1,2*- 1Department of Hematology and Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- 2Institute of Hematology, Zhejiang University, Hangzhou, China
A Corrigendum on
Subtype-specific human endogenous retrovirus K102 envelope protein is a novel serum immunosuppressive biomarker of cancer
By Gong Q and Xu R (2025) Front. Immunol. 15:1533740. doi: 10.3389/fimmu.2024.1533740
In the published article, there was two errors in the article title.
1.Instead of “*CORRESPONDENCE Rongzhen Xu email:enJ4eWsyMDI0QDE2My5jb20=”, it should be “*CORRESPONDENCE Rongzhen Xu email:enJ4eWsxMEB6anUuZWR1LmNu”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: cancer immunosuppression, endogenous retroviruses, HML-2 subtype, HERV-K102, serum biomarker
Citation: Gong Q and Xu R (2025) Corrigendum: Subtype-specific human endogenous retrovirus K102 envelope protein is a novel serum immunosuppressive biomarker of cancer. Front. Immunol. 16:1560546. doi: 10.3389/fimmu.2025.1560546
Received: 14 January 2025; Accepted: 17 January 2025;
Published: 30 January 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Gong and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Rongzhen Xu, enJ4eWsxMEB6anUuZWR1LmNu